Product Code: GDHC517DFR
Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.
Amitiza (lubiprostone) is indicated for the treatment of IBS-C in women 18 years of age and older, but only in the US. This product was developed by Sucampo Pharmaceuticals and Takeda, and initially gained approval in the US in 2006 for the treatment of chronic idiopathic constipation (CIC) in adults. In 2008, Amitiza gained a label expansion from the Food and Drug Administration (FDA) for the treatment of IBS-C in women of 18 years of age and older.
- Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Amitiza including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Amitiza for the top 2 countries from 2013 to 2023.
- Sales information covered for the US and Japan.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for IBS.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Amitiza performance.
- Obtain sales forecast for Amitiza from 2013-2023 in top 2 countries (the US and Japan).
Table of Contents
1. Table of Contents
- 1.1. List of Tables
- 1.2. List of Figures
- 2.1. Catalyst
- 2.2. Related Reports
3. Disease Overview
- 3.1. Etiology and Pathophysiology
- 3.1.1. Etiology
- 3.1.2. Pathophysiology
- 3.2. Classification
- 3.3. Symptoms
- 3.4. Prognosis
- 3.5. Quality of Life
4. Disease Management
- 4.1. Diagnosis and Treatment Overview
- 4.1.1. Diagnosis
- 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
- 4.1.3. Clinical Practice
5. Competitive Assessment
6. Amitiza (lubiprostone)
- 6.1. Overview
- 6.2. Efficacy
- 6.3. Safety
6.4. SWOT Analysis
- 7.1. Bibliography
- 7.2. Abbreviations
- 7.3. Methodology
- 7.4. Forecasting Methodology
- 7.4.1. Diagnosed IBS Patients
- 7.4.2. General Pricing Assumptions
- 7.4.3. Individual Drug Assumptions
- 7.4.4. Generic Erosion
- 7.5. Primary Research - KOLs Interviewed for This Report
- 7.6. Primary Research - Prescriber Survey
- 7.7. About the Authors
- 7.7.1. Analyst
- 7.7.2. Therapy Area Director
- 7.7.3. Global Head of Healthcare
- 7.8. About GlobalData
- 7.9. Disclaimer
List of Tables
- Table 1: Common Symptoms of IBS
- Table 2: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS
- Table 3: Treatment Guidelines for IBS
- Table 4: Leading Prescribed Drugs for IBS by Predominant Symptoms in the 7MM, 2014†
- Table 5: Leading Branded Treatments for IBS, 2014
- Table 6: Product Profile - Amitiza
- Table 7: Safety of Amitiza - Most Frequently Reported Adverse Events
- Table 8: Amitiza SWOT Analysis, 2014
- Table 9: Global IBS Sales Forecasts ($m) for Amitiza, 2013-2023
- Table 10: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country
List of Figures
- Figure 1: Summary of Pharmacotherapies Used to Treat IBS